Trialssemaglutidetirzepatideobesityclinical trialphentermine

Pilot trial tests tapering and phentermine-topiramate off-ramps from GLP-1s

The 60-person randomized feasibility study compares full-dose continuation, every-other-week tapering and a switch to non-incretin drugs over 12 months.

By Priya Raman · Science Reporter

Oct 5 08:00 ETSource: ClinicalTrials.gov

The wire

01The OFF-RAMP pilot (NCT07832084), a phase 4 trial sponsored by Jing Luo, will randomize 60 adults to three weight-maintenance strategies starting November 1, 2026.
02Clinicians fielding patient questions about stopping GLP-1s have little randomized evidence on tapering or switching; this trial is designed to test feasibility first.
03It is a pilot sized for acceptability and recruitment feasibility, not efficacy, and results depend on a larger follow-up study.

From the source

Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s
NCT07832084 · PHASE4 · NOT YET RECRUITING · Sponsor: Jing Luo · Conditions: Obesity & Overweight, Cardiometabolic Health Indicators.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT07832084